BIOPHARMACEUTICALS

TEDUGLUTIDE

Teduglutide (API) to accelerate Loose bowl syndrome therapy

Background

• Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-amino acid polypeptide and a glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
• It works by improving the absorption of fluids and nutrients in the intestines, hence used for patients who need additional nutrition or fluids from intravenous (IV) therapy.
• Our technology on Teduglutide would benefit many pharma majors to decrease their cost and time of peptide production.

Salient features Lorven’s Teduglutide

• Application ready Teduglutide Biosimilar
• High pure (96%), available at an economical price
• Expressed in E. coli expression system
• Yields up to gm/lit/hour
• Significantly reduced production cost and time

Product Quality

• 100% native confirmation
• Functionally active peptide
• Efficacy matches with the innovator reference drug
• Free from animal-derived components

Safety

E. coli: Genetically highly amenable host organism with BSL-1 maintenance.

Intellectual Property

Patent Application under process. Title: Process for improved expression of biologically active Teduglutide in E. coli expression system by strain engineering.